Robyn Karnauskas
Stock Analyst at Truist Securities
(2.33)
# 2,526
Out of 4,735 analysts
182
Total ratings
40%
Success rate
-0.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Hold | $333 → $298 | $274.81 | +8.44% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $57.04 | +13.96% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $96.24 | +14.30% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $92.96 | -10.71% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $172.61 | +21.66% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $4.25 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $140.98 | +141.17% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $3.43 | +658.02% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $1.32 | +430.30% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $687.80 | +65.02% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $3.22 | +210.56% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.22 | +179.50% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $17.88 | +313.87% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.27 | +104.08% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $23.59 | +103.48% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $14.14 | +253.61% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $742.35 | +14.50% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $427.89 | +18.72% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $26.64 | +35.14% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $45.25 | -44.75% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.36 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $62.53 | +123.89% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $1.15 | +12,943.48% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.32 | +430.30% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.91 | +268.88% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.83 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $3.06 | +847.71% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $19.61 | +1,531.82% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $7.50 | +100.00% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.41 | +466.89% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.66 | +12,873.14% | 1 | Oct 8, 2020 |
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $274.81
Upside: +8.44%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $57.04
Upside: +13.96%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $96.24
Upside: +14.30%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $92.96
Upside: -10.71%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $172.61
Upside: +21.66%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.25
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $140.98
Upside: +141.17%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $3.43
Upside: +658.02%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.32
Upside: +430.30%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $687.80
Upside: +65.02%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.22
Upside: +210.56%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.22
Upside: +179.50%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $17.88
Upside: +313.87%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.27
Upside: +104.08%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $23.59
Upside: +103.48%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $14.14
Upside: +253.61%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $742.35
Upside: +14.50%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $427.89
Upside: +18.72%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $26.64
Upside: +35.14%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $45.25
Upside: -44.75%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.36
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $62.53
Upside: +123.89%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $1.15
Upside: +12,943.48%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.32
Upside: +430.30%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.91
Upside: +268.88%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.83
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $3.06
Upside: +847.71%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $19.61
Upside: +1,531.82%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $7.50
Upside: +100.00%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $4.41
Upside: +466.89%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.66
Upside: +12,873.14%